title: Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells.
abstract: The forkhead transcription factor FOXO1, a downstream target of phosphatidylinositol-3-kinase/Akt signalling pathway, regulates cyclic differentiation and apoptosis in normal endometrium, but its role in endometrial carcinogenesis is unknown. Screening of endometrial cancer cell lines demonstrated that FOXO1 is expressed in HEC-1B cells, but not in Ishikawa cells, which in turn highly express the FOXO1 targeting E3-ubiquitin ligase Skp2. FOXO1 transcript levels were also lower in Ishikawa cells and treatment with the proteasomal inhibitor was insufficient to restore expression. Lack of FOXO1 expression in Ishikawa cells was not accounted for by differential promoter methylation or activity, but correlated with increased messenger RNA (mRNA) turnover. Comparative analysis demonstrated that HEC-1B cells proliferate slower, but are more resistant to paclitaxel-mediated cell death than Ishikawa cells, which were partially reversed upon silencing of FOXO1 in HEC-1B cells or its re-expression in Ishikawa cells. We further show that FOXO1 is required for the expression of the growth arrest- and DNA-damage-inducible gene GADD45alpha. Analysis of biopsy samples demonstrated a marked loss of FOXO1 and GADD45alpha mRNA and protein expression in endometrioid endometrial cancer compared to normal endometrium. Together, these observations suggest that loss of FOXO1 perturbs endometrial homeostasis, promotes uncontrolled cell proliferation and increases susceptibility to genotoxic insults.
authors.affiliation: 1Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital, London, UK.
authors.forename: T
authors.initials: T
authors.lastname: Goto
authors.forename: M
authors.initials: M
authors.lastname: Takano
authors.forename: A
authors.initials: A
authors.lastname: Albergaria
authors.forename: J
authors.initials: J
authors.lastname: Briese
authors.forename: K M
authors.initials: KM
authors.lastname: Pomeranz
authors.forename: B
authors.initials: B
authors.lastname: Cloke
authors.forename: L
authors.initials: L
authors.lastname: Fusi
authors.forename: F
authors.initials: F
authors.lastname: Feroze-Zaidi
authors.forename: N
authors.initials: N
authors.lastname: Maywald
authors.forename: M
authors.initials: M
authors.lastname: Sajin
authors.forename: R E
authors.initials: RE
authors.lastname: Dina
authors.forename: O
authors.initials: O
authors.lastname: Ishihara
authors.forename: S
authors.initials: S
authors.lastname: Takeda
authors.forename: E W-F
authors.initials: EW
authors.lastname: Lam
authors.forename: A M
authors.initials: AM
authors.lastname: Bamberger
authors.forename: S
authors.initials: S
authors.lastname: Ghaem-Maghami
authors.forename: J J
authors.initials: JJ
authors.lastname: Brosens
mesh_terms: D018269:Carcinoma, Endometrioid / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015536:Down-Regulation / Q000235:genetics* / Q000502:physiology; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors / Q000096:biosynthesis / Q000172:deficiency* / Q000235:genetics* / Q000502:physiology; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D042822:Genomic Instability / Q000235:genetics; D006801:Humans
chemical_list: C085126:FOXO1 protein, human; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors